1-甲基[1,3]恶唑并[5,4-b]吡啶-2(1H)-酮 | 144141-38-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 中文名称: 1-甲基[1,3]恶唑并[5,4-b]吡啶-2(1H)-酮
• 英文名称: 1-methyloxazolo[5,4-b]pyridin-2(1H)-one
• 英文别名: 1-methyl-[1,3]oxazolo[5,4-b]pyridin-2-one
• CAS: 144141-38-8
• 化学式: C₇H₆N₂O₂
• 分子量: 150.137
• InChiKey: MUVUCPQXJSHJMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氨基-2-羟基吡啶 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.67h， 生成 1-甲基[1,3]恶唑并[5,4-b]吡啶-2(1H)-酮
  参考文献：
  名称：

  Synthesis and N-substitution of an uncommon heterocyclic system: Oxazolo[5,4-b]pyridin-2(1H)-one

  摘要：

  Oxazolo[5,4-b]pyridin-2(1H)-one 2 can be obtained in a one-step procedure. Its reactivity towards nucleophiles and alkylation to nitrogen are described.

  DOI：

  10.1016/s0040-4039(00)61315-1

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• Spirolactam Bicyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090325991A1

  公开（公告）日：2009-12-31

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式：（其中变量A1、A2、A3、A4、A5、A6、A7、B、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20100093759A1

  公开（公告）日：2010-04-15

  Compounds of formula I: I (wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：I（其中变量A1、A2、B、m、n、J、R4、G1、G2、G3和Y如本文所述），它们是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS
  申请人：Merck & Co. Inc.

  公开号：EP1608627B1

  公开（公告）日：2008-05-07
• HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20180002343A1

  公开（公告）日：2018-01-04

  The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.